G2B-002
Rare pediatric solid tumors (e.g., high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma, neuroblastoma)
Pre-clinicalActive
Key Facts
Indication
Rare pediatric solid tumors (e.g., high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma, neuroblastoma)
Phase
Pre-clinical
Status
Active
Company
About Gate2Brain
Gate2Brain is a private, preclinical-stage biotech leveraging a proprietary platform of peptide shuttles to ferry diverse drug cargoes (small molecules, biologics, nanoparticles) across biological barriers. Its flagship asset, G2B-002, has received Orphan Drug Designation from both the EMA and FDA for pediatric solid tumors and is advancing toward Phase 1 trials. The company positions itself as a deep-tech player addressing significant unmet medical needs in neurology, oncology, and rare diseases through a transformative delivery technology.
View full company profile